HOUSTON--(BUSINESS WIRE)--Dec. 18, 2014--
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on
discovering and developing novel cellular immunotherapies, today
announced the pricing of its initial public offering of 7,350,000 shares
of its common stock, an increase of 1,100,000 shares from the number of
shares originally offered, at a public offering price of $19.00 per
share. All of the shares of common stock are being offered by Bellicum.
The Company's common stock has been approved for listing on the NASDAQ
Global Market and is expected to begin trading today (December 18, 2014)
under the ticker symbol "BLCM." In addition, Bellicum has granted the
underwriters a 30-day option to purchase up to an additional 1,102,500
shares of common stock at the offering price.
Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co. are
acting as joint book running managers for the offering and Trout Capital
LLC is acting as co-manager for the offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on December 17,
2014. This offering will be made only by means of a prospectus, copies
of which may be obtained from Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by email at prospectus@citi.com,
or by telephone at 1-800-831-9146; or Piper Jaffray & Co., Attention:
Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, or by telephone at 800-747-3924 or by e-mail at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on
discovering and developing novel cellular immunotherapies for various
forms of cancer, including hematological cancers and solid tumors, as
well as orphan inherited blood disorders. The Company is using its
proprietary Chemical Induction of Dimerization, or CID, technology
platform to engineer and control components of the immune system in real
time. The Company is developing next-generation product candidates in
some of the most important areas of cellular immunotherapy, including
hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy,
and dendritic cell vaccines.
Source: Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Investors:
Pete Rahmer,
646-378-2973
prahmer@troutgroup.com
Media:
Brad
Miles, 646-513-3125
bmiles@bmccommunications.com